Interestingly, both anti-VEGF/VEGFR and EGFR inhibition have already been shown to attenuate atherosclerosis in a mouse model of disease, suggestive of their promise in ASCVD therapy [70–73]. The gene discussed is EGFR; the disease is atherosclerosis.